A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group

Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving two years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared with other microtubule inhibitors, and may have antitumor activity in osteosarcoma.

[1]  J. Reid,et al.  A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) , 2018, Pediatric blood & cancer.

[2]  Robin L. Jones,et al.  Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Prados,et al.  A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.

[4]  D. Hawkins,et al.  Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[6]  R. Goldsby,et al.  Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group , 2016, Pediatric blood & cancer.

[7]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Meltzer,et al.  Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma , 2014, Clinical Cancer Research.

[9]  S. Keir,et al.  Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.

[10]  P. Adamson,et al.  Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study , 2013, Pediatric blood & cancer.

[11]  S. Klaar,et al.  The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use , 2012, Clinical Cancer Research.

[12]  M. Trivedi,et al.  Eribulin: A Novel Cytotoxic Chemotherapy Agent , 2012, The Annals of pharmacotherapy.

[13]  J. Blay,et al.  Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. , 2011, The Lancet. Oncology.

[14]  Sarika Jain,et al.  Eribulin Mesylate , 2011, Clinical Cancer Research.

[15]  Peter J Houghton,et al.  Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.

[16]  P. Adamson,et al.  A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study , 2010, Pediatric blood & cancer.

[17]  S. Altekruse,et al.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Adamson,et al.  Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group , 2010, Clinical Cancer Research.

[19]  M. Jordan,et al.  Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase , 2008, Molecular Cancer Therapeutics.

[20]  Joseph Zeidner,et al.  The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.

[21]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Ferrari,et al.  Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  A. Cantor,et al.  Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. , 1995, Medical and pediatric oncology.

[24]  A. Huvos,et al.  Osteogenic sarcoma with clinically detectable metastasis at initial presentation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Meyer,et al.  Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis , 1992, Cancer.

[26]  N. Jaffe,et al.  Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. , 1974, The New England journal of medicine.

[27]  D. James,et al.  VINCRISTINE IN CHILDREN WITH MALIGNANT SOLID TUMORS. , 1964, The Journal of pediatrics.

[28]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[29]  M. Krailo,et al.  A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. , 1987, Medical and pediatric oncology.